Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Brian Drachman et al.|New England Journal of Medicine|2018Cited by 1.4k
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosisMorie A. Gertz, Laura Obici, Morton Scheinberg et al.|Expert Review of Clinical Pharmacology|2019Cited by 39
Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)Thomas H. Brannagan, Morie A. Gertz, Annabel K. Wang et al.|Neurology|2018Cited by 2
Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001)Morie A. Gertz, Merrill D. Benson, Annabel K. Wang et al.|Neurology|2018Cited by 1
Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331)John L. Berk, Giampaolo Merlini, Annabel K. Wang et al.|Neurology|2018Cited by 0